Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma
- 5 January 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 53 (5), 763-769
- https://doi.org/10.3109/10428194.2011.626882
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and responds to standard treatment with chemoimmunotherapy in most patients. Standard prognostic scoring systems such as the International Prognostic Index (IPI) are useful for risk stratification, but are unreliable in predicting outcomes in individual patients because of the biologic heterogeneity of this disease. Gene expression profiling has revealed molecular subtypes of DLBCL: those derived from the lymph node germinal center (GCB) and others derived from an activated B-cell (ABC). A third entity, primary mediastinal B-cell lymphoma (unclassifiable DLBCL), displays pathobiologic features distinct from ABC and GCB subtypes. Patients with ABC-DLBCL have inferior progression-free survival and overall survival relative to those with the GCB subtype. In conclusion, molecular subtyping is a powerful tool for discriminating cases of DLBCL into groups that display very disparate biology and clinical outcomes. Although immunohistochemistry (IHC)-based algorithms predict both the molecular subtype as defined by gene expression profiling and clinical outcomes with reasonable concordance, not all experienced centers have been able to reproduce these findings. As techniques to subclassify DLBCL become universally adopted, large prospective trials will be needed to confirm the benefit of therapy tailored to molecular subtype.This publication has 52 references indexed in Scilit:
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Frequent inactivation of A20 in B-cell lymphomasNature, 2009
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell LymphomaScience, 2008
- Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implicationsBlood, 2006
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma CellsThe Journal of Experimental Medicine, 2001
- Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomasProceedings of the National Academy of Sciences of the United States of America, 2000
- Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomasBlood, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000